Background. Coronary artery ectasia (CAE) is an entity frequently associated with atherosclerotic coronary artery disease (CAD) in clinical practice. Although it has common risk factors with ...atherosclerotic CAD in its development, the pathophysiology of CAE is not fully known and it is not seen in every CAD suggesting that different determinants may play a pivotal role in the development of CAD. This study aimed to reveal the impact of C-peptide and diabetes mellitus (DM) on CAE and the effect of C-peptide and coronary ectasia on long-term outcomes in patients who underwent coronary angiography. Methods. A total of 6611 patients who underwent coronary angiography were followed up retrospectively, and their major adverse cardiovascular event (MACE) status of an average of sixty months was recorded. According to their angiographic features, the patients were divided into two groups those with and without CAE. MACE development was accepted as the primary endpoint. Results. A total of 552 patients had CAE and MACE developed in 573 patients. Patients with CAE and higher C-peptide levels (Q4 + Q3) showed higher rates of MACE as compared to those without CAE and lower C-peptide levels (Q1 + Q2) (20.8% vs 7.6%; 70.1% vs 29.1%; p<0.001, for both of them). In multivariate regression analysis, high C-peptide levels were determined as an independent risk factor for CAE (OR 2.417; 95% CI 2.212–2.641; p<0.001). The Kaplan–Meier cumulative survival curves showed that the risks for MACE increased as the C-peptide levels increased. The Cox regression analysis for 5-years MACE related to the plasma C-peptide levels and presence of CAE, C-peptide, and CAE were found to be independent predictors of MACE (HR = 1.255, 95% CI: 1.164–1.336, p<0.001 and HR = 1.012, 95% CI: 1.002–1.023, p=0.026, respectively). Conclusion. Our study revealed that a high C-peptide level is an independent risk factor for CAE and that CAE and C-peptide are independent predictors for the development of MACE.
Aim
to investigate whether the MAPH score, which is a new score that combines blood viscosity biomarkers such as mean platelet volume (MPV), total protein and hematocrit, can be used to predict ...thrombus burden in ST-segment elevation myocardial infarction (STEMI) patients.
Methods
A total of 473 consecutive patients with STEMI were included in the study. Intracoronary tirofiban/abciximab infusion was applied to patients with thrombus load ≥3 and these patients (n = 71) were defined as the patient group with high thrombus load. MPV, age, hematocrit and total protein values of the patients were recorded. High shear rate (HSR) and low shear rate (LSR) were calculated from total protein and hematocrit values. Cut-off values were determined for high thrombus load by using Youden index, and score was determined as 0 or 1 according to cut-offs. The sum of the scores was calculated as the MAPH score.
Results
The mean age of the patients included in the study was 59.6 ± 12.6 (n = 354 male, 74.8%). There was no difference between the groups in terms of gender, HT and DM (P = .127, P = .402 and P = .576, respectively). In the group with high thrombus load; total protein, MPV and hematocrit values were higher (P < .001, P = .001 and P = .03, respectively). Comparison of receiver operating characteristic (ROC) curve analysis revealed that the MAPH score had better performance in predicting higher thrombus load than both other self-containing parameters and HSR and LSR.
Conclusion
The MAPH score may be a new score that can be used to determine thrombus burden in STEMI patients.
Resumo Fundamento A contagem corrigida de quadros TIMI (CTFC), o grau de blush miocárdico (MBG) e a resolução do segmento ST (STR) são parâmetros utilizados para avaliar a reperfusão em nível ...microvascular em pacientes submetidos à intervenção coronária percutânea primária (ICPp). A relação fibrinogênio/albumina (FAR) tem sido associada a eventos trombóticos em pacientes com infarto do miocárdio com elevação do segmento ST (IAMCSST) e insuficiência venosa crônica. Objetivos Investigar a relação do FAR com CTFC, MBG e STR.Métodos: O estudo incluiu 167 pacientes consecutivos que foram submetidos a ICPp com sucesso para IAMCSST e alcançaram fluxo TIMI-3. Os casos foram divididos em dois grupos, FAR alto (> 0,0765) e FAR baixo (≤ 0,0765), de acordo com o valor de corte desse parâmetro na análise característica do operador do receptor (ROC). STR, CTFC e MBG foram utilizados para avaliar a reperfusão miocárdica. Valores de p<0,05 foram considerados estatisticamente significativos. Resultados O valor CTFC, escore SYNTAX, relação neutrófilos/linfócitos, lipoproteína de baixa densidade, glicose e pico de cTnT foram significativamente maiores, enquanto STR, MBG e FEVE foram menores no grupo FAR alto. A análise de correlação de Spearman revelou relação significativa entre FAR e STR (r=-0,666, p<0,001), MBG (-0,523, p<0,001) e CTFC (r=0,731, p≤0,001). De acordo com a análise de regressão logística, FAR, glicose, pico de cTnT e dor até o tempo de Balão foram os preditores independentes mais importantes de MBG 0/1, CTFC>28 e STR<50%). A análise ROC revelou que o ponto de corte o valor de FAR≥0,0765 foi preditor de STR incompleto com sensibilidade de 71,9% e especificidade de 69,8%, MBG0/1 com sensibilidade de 72,6% e especificidade de 68,6%, e CTFC>28 com sensibilidade de 76% e uma especificidade de 65,8%. Conclusões A FAR é um importante preditor independente de perfusão microvascular em pacientes submetidos a ICPp por IAMCSST.
Increased hemodynamic load in obese individuals leads to alterations in cardiac geometry and function, including the left atrium (LA). Left atrial ejection force (LAEF) is the force required for late ...diastolic filling of the left ventricle and has been shown to be associated with age, hypertension, glucose level and weight. Our aim in this study was to investigate the relationship between obesity and LAEF in middle-aged-adult individuals. For this prospective study, a total of 104 individuals, 52 healthy normal weight (BMI < 25) and 52 healthy obese (BMI>30), who were admitted to the cardiology clinic with cardiac complaints were enrolled. Detailed physical examination, anthropometric measurements, glucose levels, lipid levels, interventricular septal thickness (IVSD), left ventricular end-diastolic diameter (LVEDD) on echocardiography, left ventricular posterior wall thickness (LVPWD), left ventricular mass index (LVMI), left ventricular ejection fraction (LVEF), left atrial diameter (LAD), left atrial volume index (LAVI) and left atrial ejection force (LAEF) were calculated. Univariate and multivariate analyses were performed to determine the factors affecting LAEF. Age, male ratio, smoking rate, arterial blood pressure and lipid parameters were similar in both groups. BMI value of the normal weight group was 23.7±1.2 and 38.9±3.7 in the overweight group (p Med-Science 2023; 12(1.000): 332-7
Resumo Fundamento O diagnóstico de miocardite aguda geralmente é feito diante de parâmetros clínicos e laboratoriais, podendo, por vezes, ser confundido com doenças que compartilham de ...características clínicas semelhantes, o que dificulta o diagnóstico. Sendo assim, o uso de biomarcadores mais específicos, para além dos clássicos como a troponina, acelerará o diagnóstico. Além disso, esses biomarcadores podem nos ajudar a compreender melhor o mecanismo de desenvolvimento da miocardite e, assim, prever resultados clínicos imprevisíveis. Objetivo Este estudo tem como objetivo revelar a possível relação entre permeabilidade intestinal e miocardite aguda. Métodos Neste estudo, buscamos avaliar os níveis séricos de zonulina e presepsina em 138 indivíduos consecutivos, incluindo 68 pacientes com miocardite e outros 70 usados como grupo controle, pareados por idade, sexo e fatores de risco cardiovascular. Valores de p < 0,05 foram considerados estatisticamente significativos. Resultados Em comparação com o grupo controle, zonulina e presepsina foram significativamente maiores no grupo de pacientes com miocardite (p < 0,001, para todos). Os níveis de zonulina foram positivamente correlacionados com presepsina, pico de CK-MB e níveis máximos de troponina (r = 0,461, p < 0,001; r = 0,744, p < 0,001; r = 0,627, p < 0,001; respectivamente). Na análise de regressão, presepsina e zonulina foram determinadas como preditores independentes para miocardite (OR de 1,002, IC de 95% 1,001-1,003, p = 0,025; OR de 12,331, IC de 95% 4,261-35,689; p < 0,001; respectivamente). O valor preditivo de miocardite aguda de presepsina e zonulina na análise da curva ROC foi estatisticamente significativo (p < 0,001, para ambos). Conclusão Este estudo mostrou que a zonulina e a presepsina podem ser biomarcadores para o diagnóstico de miocardite e também podem ser alvos terapêuticos para esclarecer o mecanismo de desenvolvimento da miocardite.
Aim The primary objective of this study was to comparatively assess the effects of levosimendan and dobutamine on RVEF, right ventricular diastolic function, and hormonal balance in patients with ...biventricular heart failure. The secondary objective was to investigate the relationship between the RVEF and the peak systolic velocity (Sa), an indicator of right ventricular systolic function, as measured by tissue Doppler echocardiography from the tricuspid annulus, and by the tricuspid annular plane systolic excursion (TAPSE).Material and Methods The population of this cross-sectional, single-center, prospective study was comprised of 81 patients, who between December 2019 and January 2022, applied to the study health institution with diagnosis of ADHF. The study sample included 67 biventricular heart failure patients with left ventricular ejection fraction (LVEF) <35 % and RVEF <50 %, as measured by the ellipsoidal shell model, and who met the other study inclusion criteria. Of these 67 patients, 34 were treated with levosimendan, and 33 were treated with dobutamine. RVEF, LVEF, Sa, peak early (Ea) and peak late (Aa) annular velocities, Ea / Aa ratio, TAPSE, systolic pulmonary artery pressure (SPAP), n-terminal pro-brain natriuretic peptide (NT-pro BNP), and functional capacity (FC) were measured before treatment and at 48 hrs of treatment. The within group pre- and post-treatment differences (Δs) of these variables were compared.Results RVEF, SPAP, and BNP, and FC significantly improved in both treatment groups (p<0.05 for all). Sa (p<0.01), TAPSE (p<0.01), LVEF (p<0.01), and Ea / Aa (p<0.05) improved only in the levosimendan group. The pre- and post-treatment Δs for RVEF, LVEF, SPAP, Sa, TAPSE, FC, and Ea / Aa were higher in the levosimendan group than in the dobutamine group (p<0.05 for all).Conclusion Compared to dobutamine, levosimendan produced greater improvement in right ventricular systolic and diastolic function in patients with biventricular heart failure and in need of inotropic therapy support.
PDF
